Table 3.
Outcomes from the viral substudy
| Molnupiravir plus usual care | Usual care | Estimated treatment effect (95% CI) | p value | ||
|---|---|---|---|---|---|
| Intensive samples | |||||
| Undetectable viral load* | |||||
| Day 2 | 1/33 (3%) | 0/38 (0) | .. | .. | |
| Day 3 | 1/34 (3%) | 0/38 (0) | .. | .. | |
| Day 4 | 2/34 (6%) | 0/39 (0) | .. | .. | |
| Day 5 | 5/28 (15%) | 0/38 (0) | .. | .. | |
| Day 6 | 6/33 (18%) | 1/39 (3%) | 11·50 (1·07–123·87) | 0·044 | |
| Day 7 | 7/34 (21%) | 1/39 (3%) | 20·72 (1·12–102·23) | 0·039 | |
| Viral load† | |||||
| Day 1 | 18 589 084 (17) | 22 218 974 (15) | .. | ||
| Day 2 | 4 599 027 (39) | 12 970 986 (11) | 0·33 (0·11–1·03) | 0·056 | |
| Day 3 | 1 164 102 (30) | 2 960 745 (12) | 0·38 (0·12–1·17) | 0·092 | |
| Day 4 | 207 097 (41) | 736 604 (16) | 0·28 (0·09–0·86) | 0·026 | |
| Day 5 | 28 244 (33) | 665 281 (12) | 0·04 (0·01–0·12) | <0·0001 | |
| Day 6 | 13 145 (32) | 208 776 (19) | 0·06 (0·02–0·19) | <0·0001 | |
| Day 7 | 6603 (25) | 85 025 (24) | 0·08 (0·02–0·24) | <0·0001 | |
| All samples | |||||
| Undetectable viral load‡ | |||||
| Day 5 | 20/238 (8%) | 8/280 (3%) | 5·02 (1·61–15·68) | 0·0055 | |
| Day 14 | 96/203 (47%) | 134/241 (56%) | 0·63 (0·35–1·13) | 0·12 | |
| Viral load† | |||||
| Day 5 | 76 565 (33) | 767 941 (26) | 0·08 (0·05–0·14) | <0·0001 | |
| Day 14 | 525 (21) | 256 (11) | 1·95 (1·15–3·31) | 0·014 | |
Data are n/N (%) or geometric mean (geometric SD).
*
Firth logistic regression adjusted for sex, age, and baseline log10(viral load). Adjusted odds ratio >1 favours molnupiravir plus usual care compared with usual care only.
†
Mixed-effect model adjusted for sex, age, and baseline log10(viral load). Adjusted geometric ratio <1 favours molnupiravir plus usual care compared with usual care only.
‡
Mixed-effect logistic regression model adjusted for sex, age, and baseline log10(viral load). Adjusted odds ratio >1 favours molnupiravir plus usual care compared with usual care only.